Gene Transfer and NMR Studies in Alpha-Mannosidosis Brain. We will investigate the ability of systemic delivery of a novel adeno-associated virus (AAV) gene transfer vector to treat the central nervous system (CNS) disease in a cat model of the human lysosomal storage disease (LSD) alpha-mannosidosis (AMD). In most LSDs genetic correction of a relatively small number of mutant cells results in secretion of the normal enzyme and receptor-mediated uptake by surrounding cells, resulting in metabolic correction of the non- transduced cells. The major problem for treating the brain is that pathology is present throughout the CNS because the metabolic defect is present in all cells. Thus, treating the whole brain requires global distribution of the therapeutic normal alpha-mannosidase (MANB) enzyme. This problem is exacerbated by the enormous size difference between mouse and human brains (~3,000 fold). The domestic cat brain is an excellent intermediate in size as it is ~100 times larger than a mouse brain, while the human brain between birth and 1 year (when treatment is expected to be the most effective) is only 10-30 times larger than the cat brain. The cat brain also has a gyrencephalic cerebral cortex that is structurally much more similar to the human brain than the rodent's. Thus, the underlying premise of this translational project is that strategies developed to globally correct the AMD cat brain are more likely to translate effectively into clinical trials. We have shown in this project that AAV gene transfer into the AMD cat brain either by multiple intraparenchymal injections or by infusion into the CSF can improve clinical and histological parameters, but the correction is incomplete. Certain AAVs can enter the CNS after systemic intravascular delivery in mice and mediate widespread transduction, but in large animal brains vector distribution is much more limited. We have developed a novel AAV vector for systemic delivery that transduces neurons throughout the cerebral cortex and other regions of both cat and monkey brains. The new vector also has the novel property of efficiently delivering the gene into large brains with a single-stranded AAV vector genome, whereas previous large animal intravascular AAV delivery experiments have used self-complementary (sc)-AAVs, which are too small to accommodate the MANB cDNA (~3kb). The novel vector will be compared to other AAVs to determine if complimentary patterns of transduction occur in the CNS and other organs to improve the therapeutic effect. We also have developed MR-based imaging assays to non-invasively measure brain pathology and preliminary experiments show they can quantitatively monitor the response to AAV treatment.
The specific aims are directed towards optimizing delivery, minimizing dose, evaluating clinical and lifespan improvements, and assessing the accuracy of non- invasive imaging parameters by correlation with histopathology. Although significant progress has been made on this project to date, the treatment is still incomplete and further improvements are needed to ensure the most effective translation into a clinical protocol for human patients.

Public Health Relevance

The lysosomal storage diseases are a large group of inherited disorders that have severe disease in the brain. We are studying gene therapy methods to correct the brain disease. The proposed studies are directed towards improving gene and protein delivery sufficiently to make them feasible for human clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK063973-11
Application #
9357607
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Eggerman, Thomas L
Project Start
2002-09-03
Project End
2020-08-31
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
11
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Castle, Michael J; Turunen, Heikki T; Vandenberghe, Luk H et al. (2016) Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. Methods Mol Biol 1382:133-49
Kumar, Manoj; Duda, Jeff T; Yoon, Sea Young et al. (2016) Diffusion Tensor Imaging for Assessing Brain Gray and White Matter Abnormalities in a Feline Model of ?-Mannosidosis. J Neuropathol Exp Neurol 75:35-43
Yoon, Sea Young; Bagel, Jessica H; O'Donnell, Patricia A et al. (2016) Clinical Improvement of Alpha-mannosidosis Cat Following a Single Cisterna Magna Infusion of AAV1. Mol Ther 24:26-33
Yoon, Sea Young; Gay-Antaki, Carlos; Ponde, Datta E et al. (2014) Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene. Mol Ther Methods Clin Dev 1:14016
Jensen, Janlee A; Brice, Angela K; Bagel, Jessica H et al. (2013) Hypervitaminosis D in guinea pigs with ?-mannosidosis. Comp Med 63:156-62
Simonato, Michele; Bennett, Jean; Boulis, Nicholas M et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:298
Tremblay, Jacques P; Xiao, Xiao; Aartsma-Rus, Annemieke et al. (2013) Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther 21:266-8
Simonato, Michele; Bennett, Jean; Boulis, Nicholas M et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:277-91
Magnitsky, Sergey; Vite, Charles H; Delikatny, Edward J et al. (2010) Magnetic resonance spectroscopy of the occipital cortex and the cerebellar vermis distinguishes individual cats affected with alpha-mannosidosis from normal cats. NMR Biomed 23:74-9
Wolfe, John H (2009) Gene therapy in large animal models of human genetic diseases. Introduction. ILAR J 50:107-11

Showing the most recent 10 out of 20 publications